Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

American journal of hematology - 1 Mar 2018

Tefferi Ayalew, Nicolosi Maura, Mudireddy Mythri, Szuber Natasha, Finke Christy M, Lasho Terra L, Hanson Curtis A, Ketterling Rhett P, Pardanani Animesh, Gangat Naseema, Mannarelli Carmela, Fanelli Tiziana, Guglielmelli Paola, Vannucchi Alessandro M

Abstract excerpt

The 2013 discovery of calreticulin (CALR) mutations in myeloproliferative neoplasms was attended by their association with longer survival in primary myelofibrosis (PMF). Subsequent studies have suggested prognostic distinction between type 1/like and type 2/like CALR mutations and detrimental effect from triple-negative mutational status. Among 709 Mayo Clinic patients with PMF, 467 (66%) harbored JAK2, 112...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Kaplan-Meier Estimate

Share to Leukemia, Myeloid, Acute

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Share to Repressor Proteins

Source

Identifiers

PMID: 29164670
DOI: 10.1002/ajh.24978

Genes

CALR
ASXL1
JAK2
MPL
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.PMID 29164670Read ↗

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosisSemantic proximity Read ↗

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.Semantic proximity Read ↗

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.Semantic proximity Read ↗

Driver mutations in primary myelofibrosis and their implications.Semantic proximity Read ↗

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsSemantic proximity Read ↗

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review.Semantic proximity Read ↗

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.Semantic proximity Read ↗

The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis.Semantic proximity Read ↗

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisionsSemantic proximity Read ↗

Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Semantic proximity Read ↗

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impactSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.